Vikram Arya
Overview
Explore the profile of Vikram Arya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arya V, Ma J, Kvitne K
Pharmaceutics
. 2024 Jul;
16(7).
PMID: 39065552
The evaluation of transporter-mediated drug-drug interactions (DDIs) during drug development and post-approval contributes to benefit-risk assessment and helps formulate clinical management strategies. The use of endogenous biomarkers, which are substrates...
2.
Tunehag K, George B, Samuels S, Vo K, Arya V, Abulwerdi G, et al.
J Clin Pharmacol
. 2024 Jan;
64(6):697-703.
PMID: 38294346
Food effect (FE) studies characterize food-drug interactions that may alter the efficacy or safety of a drug, but these studies are not conducted in pediatric patients. Pediatric patients have substantial...
3.
van den Anker J, Arya V, Knibbe C, Zhou H
J Clin Pharmacol
. 2023 Nov;
64(1):7-9.
PMID: 38017359
No abstract available.
4.
Chothe P, Arya V, Prasad B, Ramsden D, Taskar K
Drug Metab Dispos
. 2023 Sep;
51(12):1547-1550.
PMID: 37775331
Drug-metabolizing enzymes and transporters (DMETs) are key regulators of the pharmacokinetics, efficacy, and toxicity of therapeutics. Over the past two decades, significant advancements in in vitro methodologies, targeted proteomics, in...
5.
Arya V, Hodowanec A, Troy S, Struble K
Clin Infect Dis
. 2022 Nov;
75(Suppl 4):S498-S501.
PMID: 36410378
The landscape for the development of therapeutics for prevention and treatment of human immunodeficiency virus (HIV)-1 infection has pivoted towards long-acting antiretrovirals (LA-ARVs). LA-ARVs have the potential to transform global...
6.
Jing X, Arya V, Reynolds K, Rogers H
Drug Metab Dispos
. 2022 Nov;
51(2):193-198.
PMID: 36332914
RNA-based oligonucleotide therapeutics are revolutionizing drug development for disease treatment. This class of therapeutics differs from small molecules and protein therapeutics in various ways, including both its mechanism of action...
7.
Volpe D, Joshi A, Arya V
Xenobiotica
. 2022 Oct;
52(7):751-757.
PMID: 36218364
bidirectional assays are employed to determine whether a drug is a substrate and/or inhibitor of P-glycoprotein (P-gp) transport. Differences between cell lines and calculation methods can lead to variations in...
8.
Chan-Tack K, Sampson M, Earp J, Arya V, Yao L, Alexander J, et al.
J Clin Pharmacol
. 2022 Sep;
63(2):259-265.
PMID: 36149807
The US Food and Drug Administration is committed to the development of effective antiviral regimens for pediatric patients with coronavirus disease 2019 (COVID-19), including infants and neonates. On April 25,...
9.
Arya V, Reynolds K, Yang X
J Clin Pharmacol
. 2022 Jul;
62(12):1501-1506.
PMID: 35778968
Comprehensive characterization of transporter mediated drug-drug interactions (DDIs) is important to formulate clinical management strategies and ensure the safe and effective use of concomitantly administered drugs. The potential of a...
10.
Fan J, Yang Y, Grimstein M, Zhang X, Kitabi E, Earp J, et al.
Clin Pharmacol Ther
. 2021 Oct;
111(3):624-634.
PMID: 34656075
Remdesivir (RDV) is the first drug approved by the US Food and Drug Administration (FDA) for the treatment of coronavirus disease 2019 (COVID-19) in certain patients requiring hospitalization. As a...